Qed Therapeutics, A Bridgebio Company
Clinical trials sponsored by Qed Therapeutics, A Bridgebio Company, explained in plain language.
-
Experimental drug aims to help kids with genetic short stature grow taller
Disease control ENROLLING_BY_INVITATIONThis study is testing whether a drug called infigratinib can safely help children with hypochondroplasia, a genetic condition that causes short stature, grow faster and taller. It involves children aged 3 to 18 who have already been in a related observational study. The research …
Phase: PHASE2, PHASE3 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Extended trial tests growth drug for kids with rare genetic condition
Disease control ENROLLING_BY_INVITATIONThis study continues testing an experimental drug called infigratinib in children with hypochondroplasia, a genetic condition that causes short stature. It follows children who completed a previous study to monitor the drug's long-term safety and whether it helps with growth and …
Phase: PHASE2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
Daily pill aims to help kids with dwarfism grow taller and healthier
Disease control ENROLLING_BY_INVITATIONThis study is testing the long-term safety and effectiveness of a daily oral medication called infigratinib in children with achondroplasia, the most common form of dwarfism. It aims to see if the drug can help children grow taller at a rate closer to average, improve their body …
Phase: PHASE2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC